Biotech Values

[drbio45]

Omapro is currently conducting a pivotal trial in all comers with an 85 percent response rate in patients that have failed Gleevec, Sprycel and Tasigna.

At this point it doesn't matter. Ariad was looking for a quick way on to the market so they were speaking about doing a pivotal trial for the t315i mutation.

IF they get to do an open label study in the mutation, fine, I am tired of writing about it. Omapro is not just targeting the t315i, they just did that to get on the market quicker, and they were able to do an open label phase 2 study because nothing else worked.

Once Omepro is on the market, Ariad can't go to the fda and say that nothing else works, can we run an open label study?